Trial Profile
Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Dec 2015
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 22 Dec 2015 New trial record